CL Colgate-Palmolive
Mature oral care franchise trading at a premium to its slow-growth, margin-compressed reality.
The story
Colgate-Palmolive is a mature global consumer staples franchise with dominant oral care market share, but revenue growth has decelerated to low single digits as emerging markets mature and developed markets saturate. The recent margin compression from ~21% to ~15% reflects commodity cost pressure and elevated advertising spend, and while margins should partially recover, the era of 20%+ operating margins is unlikely to return sustainably. The business is in late maturity—predictable, cash-generative, but with limited reinvestment runway and excess returns eroding gradually.
Revenue growth of 3.5% in year one reflects Colgate's historical ~4% CAGR tempered by recent deceleration, converging to 2% terminal growth—below the risk-free rate—as oral care categories mature globally. Target margin of 19% splits the difference between the unsustainable 21% peak and the current depressed 15%, reflecting a realistic normalization as cost pressures ease but higher ad spend persists. Sales-to-capital of 2.62 matches the actual five-year average, and a 7-year horizon is appropriate for a mature franchise with diminishing but still positive excess returns.
Value drivers
| Revenue growth (Y1) | 3.5% |
| Terminal growth | 2.0% |
| Forecast horizon | 7y |
| Target operating margin | 19.0% |
| Years to target margin | 5 |
| Sales-to-capital | 2.62 |
| Beta | 0.70 |
| Failure probability | 0.0% |
| Cost of capital (WACC) | 7.8% |
| Terminal WACC | 9.0% |
Valuation bridge
| PV of explicit FCFF | 14.98B |
| PV of terminal value | 26.84B |
| Equity value | 34.80B |
| ÷ shares → per share | $43.66 |
News
neutral -0.10 · 8 articles
- Colgate’s Steady Dividend and Premium Push Might Change The Case For Investing In Colgate-Palmolive (CL)
- One of These Dividend Kings Pays Out More Than It Earns. Which Dividend Is Safer?
- Colgate-Palmolive (CL) Lifts Ad Spend As Fair Value Debate Hangs On North America Recovery
- Newell's Stock Surges 51% in 6 Months: Is It Time to Buy or Wait?
- Can Colgate Revive North America Growth in the Second Half?
- Nestlé, PepsiCo join forces on paper packaging push
- 6 CPGs team up on paper flexibles R&D
- U.S. war with Iran has cost $38B and is running at $3B per month, CBO says
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 21.78B | 3.5% | 16.0% | 2.57B | 281.15M | 2.29B | 2.12B |
| 2 | 22.49B | 3.2% | 16.7% | 2.78B | 270.20M | 2.51B | 2.16B |
| 3 | 23.17B | 3.0% | 17.5% | 2.99B | 257.53M | 2.73B | 2.19B |
| 4 | 23.80B | 2.8% | 18.2% | 3.21B | 243.15M | 2.97B | 2.20B |
| 5 | 24.40B | 2.5% | 19.0% | 3.43B | 227.12M | 3.20B | 2.20B |
| 6 | 24.95B | 2.2% | 19.0% | 3.50B | 209.52M | 3.29B | 2.10B |
| 7 | 25.45B | 2.0% | 19.0% | 3.57B | 190.43M | 3.38B | 2.00B |
Key risks
- Commodity cost inflation persisting longer than expected, preventing margin recovery toward 19%
- Private-label encroachment in oral care eroding Colgate's pricing power and market share
- Emerging market currency volatility and macro weakness depressing international revenue growth
Catalysts
- Premiumization strategy in oral care (electric toothbrushes, specialty toothpaste) accelerating revenue growth above 4%
- Margin recovery as commodity costs normalize and productivity savings from restructuring program materialize